Table 1.
LncRNAs and their partners involved in the atherothrombotic disease
| LncRNAs/ partners | Phenotype | Putative human orthologue identified | Data on functional conservation | ref |
|---|---|---|---|---|
| lncLSTR/TDP-43 | Plasma triglyceride levels, bile acid biosynthesis | No | No | 10 |
| Lexis/Raly | Serum cholesterol levels, hepatic sterol content | Yes | No | 11, 12 |
| HULC | Lipogenesis | Yes | Yes | 13 |
| APOA1-AS | lipid transport | Yes | Yes | 14 |
| Noncoding region between Igf2 and H19 | fat deposition and obesity | 16 | ||
| LINC00237 | MOMO Syndrome | Yes | Yes | 17 |
| Noncoding RNA from chromosome 15q11-q13 |
Prader-Willi syndrome Obesity |
No | No |
17 18 |
| IPW | PWS | Yes | Yes | 19 |
| SRA/ PPARγ | adipogenesis | Yez | Yes | 22 |
| Blnc1/EBF-2 | thermogenesis | Yes | Yes | 23 |
| PLUTO/PDX1 | type 2 diabetes, glucose tolerance | Yes | Yes | 25 |
| Betalinc1 | normal islet cell formation | No | No | 27 |
| Flicr | promoting autoimmune diabetes | Yes | Yes | 28 |
| Gas5 | correlating with type 2 diabetes risk, regulating vascular remodeling in hypertensive rats | Yes | Yes | 31 |
| Lnc-Ang362 | Regulation of proliferation of VSMC | No | No | 32 |
| MANTIS/brg1 | Modulating endothelial function | Yes | Yes | 35 |
| ANRIL | Systemic hypertension and vascular aneurysms | Yes | Yes | 36–38 |
| KCNQ1OT1 | Myocardial infarction | Yes | Yes | 45 |
| RP5-833A20.1/NFIA | Function in foam-cell macrophages | Yes | Yes | 46 |
| MeXis/ Abca1 | foam cell formation and atherosclerosis | Yes | Yes | 47, 48 |
| Lnc-DC/ STAT3 | enhancing T cell activation | Yes | Yes | 49 |
| Linc-Cox2 | Regulation of inflammatory genes | No | No | 50 |
| LincRNA-EPS | Regulation of inflammatory genes | Yes | No | 51 |
| NeST | Altering chromatin methylation pattern at interferon gamma locus in T cells | Yes | Yes | 52 |
| HIF1A-AS1 | Promoting proliferation and suppressing apoptosis of HUVECs | Yes | Yes | 55 |
| tie-1AS | Differentially regulated in samples from infants and children with various vascular malformations | Yes | Yes | 56 |
| MALAT1 | Influencing proliferation of endothelial cells in vivo and neonatal retina vascularization | Yes | Yes | 59 |
| Meg3 | Controlling endothelial function | Yes | Yes | 60 |
| ENCR | Influence smooth muscle contractile machinery and inflammatory mediators | Yes | Yes | 61 |
| lincRNA-p21/hnRNP-K | Neointimal hyperplasia, coronary artery | Yes | Yes | 62, 63 |
| SMILR | In response to interleukin-1α and PDGF stimulation | Yes | Yes | 64 |
| TERMINATOR | Cardiovascular development | Yes | Yes | 65 |
| ALIEN | Cardiovascular development | Yes | Yes | 65 |
| PUNISHER | Cardiovascular development | Yes | Yes | 65 |